Unram Medical Journal,
Год журнала:
2023,
Номер
12(2), С. 217 - 221
Опубликована: Июнь 30, 2023
Cancer
is
the
biggest
cause
of
death
in
world,
around
10
million
deaths
are
caused
by
cancer.
In
2020,
17
new
cases
were
recorded,
which
8.5
people
died
each
yearfrom
cancer,while
66%
ofpatients
canlive
up
to
5years
after
being
diagnosed
and
40%
patients
can
live
more
than
years
diagnosed.
Various
prevention
efforts
against
risk
factors
have
been
carried
out.
The
main
modalities
cancer
therapy
today
surgery,
chemotherapy,
radiation
with
choice
based
on
stage
Research
shows
that
giving
omega-3
supplementation
undergoing
chemotherapy
considered
very
beneficial
because
works
synergistically
chemotherapeutic
agents
also
be
used
increase
radiosensitivity
tumor
cells
so
it
has
a
good
impact
success
therapy.
Tumor
suppressor
p53
can
transcriptionally
activate
downstream
genes
in
response
to
stress,
and
then
regulate
the
cell
cycle,
DNA
repair,
metabolism,
angiogenesis,
apoptosis,
other
biological
responses.
has
seven
functional
domains
12
splice
isoforms,
different
subtypes
play
roles.
The
activation
inactivation
of
are
finely
regulated
associated
with
phosphorylation/acetylation
modification
ubiquitination
modification,
respectively.
Abnormal
is
closely
related
occurrence
development
cancer.
While
targeted
therapy
signaling
pathway
still
its
early
stages
only
a
few
drugs
or
treatments
have
entered
clinical
trials,
new
ongoing
trials
expected
lead
widespread
use
signaling-targeted
cancer
treatment
future.
TRIAP1
novel
inhibitor
apoptosis.
homolog
yeast
mitochondrial
intermembrane
protein
MDM35,
which
tumor-promoting
role
by
blocking
mitochondria-dependent
apoptosis
pathway.
This
work
provides
systematic
overview
recent
basic
research
progress
proposes
that
an
important
therapeutic
target
signaling.
Molecular Biology Reports,
Год журнала:
2024,
Номер
51(1)
Опубликована: Янв. 25, 2024
Abstract
Increasing
evidence
suggests
that
key
cancer-causing
driver
genes
continue
to
exert
a
sustained
influence
on
the
tumor
microenvironment
(TME),
highlighting
importance
of
immunotherapeutic
targeting
gene
mutations
in
governing
progression.
TP53
is
prominent
suppressor
encodes
p53
protein,
which
controls
initiation
and
progression
different
types.
Wild-type
maintains
cell
homeostasis
genomic
instability
through
complex
pathways,
mutant
(Mut
p53)
promotes
occurrence
development
by
regulating
TME.
To
date,
it
has
been
wildly
considered
able
mediate
immune
escape.
Herein,
we
summarized
relationship
between
tumors,
discussed
mechanism
Mut
mediated
escape,
progress
applying
protein
immunotherapy.
This
study
will
provide
basic
basis
for
further
exploration
therapeutic
strategies
protein.
BMC Gastroenterology,
Год журнала:
2025,
Номер
25(1)
Опубликована: Фев. 17, 2025
Tumor
blood
vessels
are
tortuous
and
dilated,
contributing
to
the
aberrant
tumor
microenvironment.
CD93
is
a
newly
reported
transmembrane
receptor,
mainly
expressed
in
endothelial
cells,
that
has
demonstrated
prognostic
value
some
cancer
types.
However,
role
of
vasculature
colorectal
(CRC)
tissues
its
significance
remain
unknown.
It
therefore
necessary
explore
effect
patients
with
CRC.
We
detected
expression
human
CRC
using
immunohistochemistry.
then
examined
correlation
between
clinicopathological
factors
from
134
levels
were
higher
than
adjacent
normal
tissues.
Upregulation
was
associated
site
microsatellite
instability.
protein
positively
related
macrophage
infiltration
High
may
indicate
normalization
better
overall
survival.
highly
correlated
immune
cells.
Our
findings
reveal
vascular
patient
prognosis
can
be
predicted
by
detecting
Breast
cancer
is
the
most
prevalent
malignancy
and
leading
cause
of
cancer-related
deaths
among
women
worldwide.
Several
case
reports
have
shown
that
some
breast
patients
subsequently
develop
acute
myeloid
leukemia
(AML)
within
a
short
period.
However,
causal
relationship
pathogenic
mechanisms
between
AML
remain
incompletely
understood.
Mendelian
randomization
(MR)
analyses
were
conducted
to
explore
bidirectional
relationships
AML.
Additionally,
we
applied
Bayesian
Weighted
Randomization
(BWMR)
approach
validate
results
MR
analysis.
Subsequently,
utilized
RNA-seq
data
from
various
sources
potential
molecular
signaling
pathways
Both
IVW
method
BWMR
demonstrated
three
distinct
consistently
indicated
as
risk
factor
for
AML,
with
all
showing
statistically
significant
(all
P
<
0.05,
Odds
Ratios
[ORs]
>
1).
Bioinformatic
suggested
extracellular
vesicle
functions
p53
pathway
may
mediate
links
Using
machine
learning,
identified
8
genes
high
diagnostic
efficacy
predicting
occurrence
in
patients.
transcriptome
analysis
offered
theoretical
basis
understanding
therapeutic
targets
Frontiers in Molecular Biosciences,
Год журнала:
2024,
Номер
10
Опубликована: Янв. 11, 2024
Serine
protease
inhibitor
E
(SERPINE)
family
genes
participate
in
the
tumor
growth,
cancer
cell
survival
and
metastasis.
However,
SERPINE
members
role
prognosis
their
clinical
therapeutic
potentials
various
human
types
have
not
been
elaborately
explored.
Laboratory Medicine,
Год журнала:
2024,
Номер
55(6), С. 686 - 699
Опубликована: Июль 13, 2024
Abstract
Genetic
alterations
that
affect
the
function
of
p53
tumor
suppressor
have
been
extensively
investigated
in
myeloid
neoplasms,
revealing
their
significant
impact
on
disease
progression,
treatment
response,
and
patient
outcomes.
The
identification
characterization
TP53
mutations
play
pivotal
roles
subclassifying
neoplasms
guiding
decisions.
Starting
with
presentation
a
typical
case,
this
review
highlights
complicated
nature
genetic
involving
provides
comprehensive
analysis
other
neoplasms.
Currently
available
methods
used
clinical
laboratories
to
identify
are
discussed,
focusing
importance
establishing
robust
testing
protocol
within
ensure
delivery
accurate
reliable
results.
implications
trial
options
reviewed.
Ultimately,
we
hope
valuable
insights
into
patterns
offers
guidance
establish
practical
laboratory
protocols
support
best
practices
precision
oncology.
Cancer Letters,
Год журнала:
2024,
Номер
600, С. 217185 - 217185
Опубликована: Авг. 12, 2024
Glioblastoma,
a
highly
malignant
intracranial
tumor,
has
acquired
slow
progress
in
treatment.
Previous
clinical
trials
involving
targeted
therapy
and
immune
checkpoint
inhibitors
have
shown
no
significant
benefits
treating
glioblastoma.
This
ineffectiveness
is
largely
due
to
the
complex
immunosuppressive
environment
of
Glioblastoma
cells
exhibit
low
immunogenicity
strong
heterogeneity
microenvironment
replete
with
inhibitory
cytokines,
numerous
cells,
insufficient
effective
T
cells.
Fortunately,
recent
Phase
I
CART
for
glioblastoma
confirmed
its
safety,
small
subset
patients
achieving
survival
benefits.
However,
continues
face
challenges,
including
blood-brain
barrier
obstruction,
antigen
loss,
an
tumor
(TME).
article
provides
detailed
examination
glioblastoma's
microenvironment,
both
from
intrinsic
extrinsic
cell
factors,
reviews
current
basic
research
on
multi-targets
treatment,
concludes
by
outlining
key
challenges
using
therapy.
